Testis-specific protein Y-encoded (TSPY) is the putative gene for the gonadoblastoma locus on the Y chromosome (GBY). TSPY and an X-homologue, TSPX, harbor a conserved domain, designated as SET/NAP domain, but differ at their C termini. Ectopic expression of TSPY accelerates cell proliferation by abbreviating the G 2 /M stage, whereas overexpression of TSPX retards cells at the same stage of the cell cycle. Previous studies demonstrated that the SET oncoprotein is capable of binding to cyclin B. Using various protein interaction techniques, we demonstrated that TSPY and TSPX indeed bind competitively to cyclin B at their SET/NAP domains in vitro and in vivo. TSPY colocalizes with cyclin B1 during the cell cycle, particularly on the mitotic spindles at metaphase. TSPY enhances while TSPX represses the cyclin B1-CDK1 phosphorylation activity. The inhibitory effect of TSPX on the cyclin B1-CDK1 complex has been mapped to its carboxyl acidic domain that is absent in TSPY, suggesting that TSPX could serve a normal function in modulating cell-cycle progression at the G 2 /M stage, whereas TSPY has acquired a specialized function in germ cell renewal and differentiation. Epigenetic dysregulation of TSPY in incompatible germ or somatic cells could promote cell proliferation and predispose susceptible cells to tumorigenesis.
Introduction
The testis-specific protein Y-encoded (TSPY) is the putative gene for the gonadoblastoma locus on the Y chromosome (GBY) that predisposes dysgenetic gonads in XY sex-reversed patients and intersex individuals to gonadoblastoma development (Page, 1987; Lau, 1999) . The 2.8-kb TSPY transcriptional unit is embedded in a 20.4-kb DNA fragment that is repeated tandemly at the critical region for GBY on the short arm, proximal to the centromere, of the human Y chromosome (Skaletsky et al., 2003) . The number of TSPY repeats varies from B23 to 64 among phenotypically normal individual males (Repping et al., 2006) , but could change under certain disease conditions (Vijayakumar et al., 2006) , suggesting the possibility of genomic instability in this region of the chromosome. TSPY is normally expressed in early gonocytes and prespermatogonia in fetal testis and in spermatogonia, spermatocytes and round spermatids in adult testis (Honecker et al., 2004; Kido and Lau, 2005) , and has been postulated to serve normal functions in stem germ cell proliferation and meiotic division (Schnieders et al., 1996; Lau, 1999) . TSPY is ectopically expressed in tumor cells in various types of germ cell tumors, including gonadoblastoma, testicular germ cell tumors and male intracranial germ cell tumors, and has been considered as a key marker that is important in the pathogenesis of these types of human tumors Kersemaekers et al., 2005; Hoei-Hansen et al., 2006; Oram et al., 2006; Li et al., 2007b) . Significantly, it is also aberrantly expressed in prostate cancer and numerous somatic cancers, including hepatocellular carcinoma and melanoma of male origins (Lau and Zhang, 2000; Lau et al., 2003; Gallagher et al., 2005; Yin et al., 2005) , suggesting that the TSPY tandem arrays are hot spots for epigenetic dysregulation. Currently, the exact mechanism(s) by which TSPY exerts its putative oncogenic functions on these somatic cancers is uncertain.
The highly conserved 2.8-kb TSPY transcriptional unit is capable of producing a variety of transcripts with alternative splicing mechanisms (Krick et al., 2003; Lau et al., 2003) . The predominant TSPY (type 1) transcript encodes a 38-kDa phosphoprotein of 308 amino acids. The open reading frames of variant transcripts, however, are in-frame with that of the type 1 TSPY transcript and encode polymorphic TSPY proteins with various interstitial in-frame deletions between exons 1 and 2. Significantly, all TSPY isoforms harbor the entire or part of a conserved domain of B160 amino acids, termed SET/NAP domain initially identified in the human SET oncoprotein and nucleosome assembly protein-1 (NAP-1) (Tsuchiya et al., 1995; Vogel et al., 1998) . The SET/NAP proteins are structurally related and serve a wide range of biological functions, including cell-cycle regulation, histone chaperone, chromatin organization, transcription modulation and steroid receptor co-regulation (Adachi et al., 1994; Kellogg et al., 1995; Estanyol et al., 1999; Compagnone et al., 2000; Chai et al., 2001; Seo et al., 2001; Canela et al., 2003; Ozbun et al., 2003; Gamble et al., 2005; Kandilci and Grosveld, 2005; Vera et al., 2005; Kido and Lau, 2006) . Currently, it is uncertain if these TSPY isoforms possess the same or different functions, retention of the SET/NAP domain suggests that this conserved domain could be important for their biological action(s).
Ectopic expression of TSPY accelerates proliferation in cultured cells and promotes tumorigenesis in athymic mice (Oram et al., 2006) . TSPY mediates such proliferative properties by, either directly or indirectly, upregulating pro-growth genes and repressing apoptosis genes and growth inhibitors. Specifically, cells overexpressing TSPY transit the G 2 /M phase of the cell cycle more rapidly than those without TSPY expression. These observations are in contrast to those of the SET oncoprotein and cell division autoantigen-1 (CDA1) (Chai et al., 2001; Canela et al., 2003) . CDA1 and the differentially expressed nucleolar TGF-b1 target (DENTT) (Ozbun et al., 2001 (Ozbun et al., , 2003 are isoforms encoded by the X-homologue of TSPY, which has recently been designated as TSPX (Delbridge et al., 2004) . CDA1 differs from DENTT by 60 additional amino acids at its N terminus. Overexpression of either TSPX (CDA1) or SET retards/arrests cell-cycle progression at G 2 /M stage (Chai et al., 2001; Canela et al., 2003) . Further studies on the SET oncoprotein suggest that it could mediate such cell-cycle regulatory function(s) by interacting with cyclin B, the mitotic cyclin important for G 2 /M progression (Canela et al., 2003) .
To address the probable mechanism(s) by which TSPY exerts its cell-cycle regulatory functions, we had conducted a series studies designed to investigate the possible TSPY-cyclin B interaction, and consequences thereof on the cyclin-dependent kinase activities. TSPX and SET were studied in parallel experiments as references. Our results demonstrated that TSPY interacted with all three types of cyclin B, that is, cyclin B1, B2 and B3, at its SET/NAP domain. It enhanced the phosphorylation activities of an activated cyclin B1-CDK1 complex on its targets in vitro and in vivo. TSPY colocalized with the endogenous cyclin B1 in transfected cells at various cell-cycle stages, including mitosis. Significantly, TSPX and SET also bound cyclin B1, but exerted inhibitory effects on cyclin B-CDK1 activities in the same assay. The inhibitory domains of TSPX and SET were mapped to their respective acidic carboxyl domain, which is absent in TSPY. Such structural differences between TSPY and TSPX/SET could be responsible for the respective effects on cell-cycle progression.
Results

TSPY and TSPX bind cyclin B competitively at their SET/NAP domain
Previously we demonstrated that overexpression of TSPY accelerated cell proliferation in vitro and in vivo by shortening the G 2 /M stage of the cell cycle (Oram et al., 2006) . As SET/NAP domain proteins had been demonstrated to bind type B cyclins (Kellogg et al., 1995) , which is critical for G 2 /M progression, we surmised that TSPY could exert its cell-cycle regulatory effects by interacting with the mitotic cyclins. To explore this possibility, various recombinant glutathione Stransferase (GST) fusion proteins were synthesized in bacteria and used in GST pull-down assays with the respective 35 S-labeled interactive candidate proteins. Using GST fusion proteins of human cyclin A, B1, B2 (Pines and Hunter, 1992) and B3 (transcript 2 coding for the short version of this meiotic cyclin (Tschop et al., 2006) ) as baits, the type 2 TSPY variant protein was consistently retained with GST-cyclin B1, B2 and B3 proteins, but not that of cyclin A (Figure 1a ). The cDNA for type 2 TSPY was originally isolated in our laboratory (Zhang et al., 1992) . It differs from the predominant type 1 transcript at its 3 0 ends due to utilization of a cryptic splice acceptor site 11 nucleotides ahead of that for type 1 transcript at the fifth exon and encodes a protein of 294 amino acids (Lau et al., 2003) . TSPY proteins encoded by both type 1 and 2 transcripts harbor an identical SET/NAP domain but differ slightly at their C termini with divergent amino acids at residue no. 279 and beyond. To confirm the cyclin B interaction with other TSPY variants, GST-cyclin B1 fusion protein was used as bait in binding assays with similarly labeled TSPY isoforms. Our results showed that the GST-cyclin B1 bait pulled down all TSPY isoforms, for example, type 1, Exon1A, Exon1C and Intron4 ( Figure 1b) . As the X-homologue, TSPX, and TSPY are highly conserved at the SET/NAP domain (Delbridge et al., 2004; Lau et al., 2007) , we had explored the possibility that TSPX could also bind cyclin B in similar assays. Using GST-cyclin B1 and B2 and labeled TSPX, we were able to confirm the interactions between cyclin B and TSPX (Figure 1c ) in similar pull-down experiments. Interestingly, GST-TSPY binding to labeled cyclin B1 could be effectively abolished with increasing amounts of recombinant TSPX protein (Figure 1d ), suggesting that their bindings to cyclin B1 are competitive in nature.
To define the cyclin B-binding domain on TSPY, various deletion mutants were generated with the type 1 TSPY cDNA (Figures 2A, a-f ) and analysed with pulldown assays using GST-cyclin B1 fusion protein as bait. The results showed that there were two potential sites (residue nos. 152-180 and 181-265) within the SET/NAP domain on TSPY that were capable of binding to cyclin B1 ( Figure 2B ). Pull-down assays with labeled cyclin B1 and GST fusion proteins harboring the N terminus (residue nos. 1-120), SET/NAP domain (residue nos. 121-265) and C terminus (residue nos. 266-308) of TSPY confirmed the SET/NAP domain as the cyclin B-binding domain for TSPY ( Figure 2C ). As TSPY binding to cyclin B could be effectively abolished by excess TSPX, we surmised that TSPY and TSPX could possess cyclin B-binding domains at their SET/ NAP regions. Using the ClustalW Protein Alignment program on the two proteins, we had identified two regions, that is, residue nos. 152-180 and 203-220, within this conserved domain of TSPY that shared significant homologies with the corresponding regions of TSPX ( Figure 2F ). To further define the cyclin Bbinding domain of TSPY, three peptides (that is, g-152-180, h-165-180 and i-203-220) corresponding to these regions were synthesized, conjugated to Sepharose resin and used as baits in pull-down experiments. The results showed that cyclin B1 bound to all three peptides ( Figure 2D ). To address whether the same regions within the TSPX protein could also be interactive domains for cyclin B1, peptides corresponding to residue nos. 271-286 and 310-327 of TSPX were synthesized and used in similar binding assays with 35 S-labeled cyclin B1 protein. Our results showed that indeed these TSPX peptides were capable of retaining the labeled cyclin B1 ( Figure 2E ), suggesting that cyclin B1 bound to TSPY and TSPX in two specific sites, respectively at residue nos. 152-180 and 203-220 of TSPY and residue nos. 271-286 and 310-327 of TSPX.
To demonstrate similar interactions in vivo between cyclin B1 and TSPY and TSPX, FLAG epitope-tagged expression vectors for respective proteins were transiently transfected to human HEK293 cells. The expressed proteins were immunoprecipitated with a specific antibody against FLAG and analysed by western blotting using specific antibodies against the FLAG fusion proteins, cyclin B1 and CDK1. Epitope-tagged proteins were detected only in cells transfected with the respective gene-expression vectors ( Figure 3 , lanes a2, 4; lanes b2, 3, 5, 6), but not in those transfected with cloning vector alone ( Figure 3 , lanes a1, 3; lanes b1, 4), in both the total cell lysates and those immunoprecipitated with FLAG antibody. Reprobing the filters with antibodies specifically against cyclin B1 and CDK1 showed that both endogenous proteins were expressed in the transfected cells, as detected in the total cell lysates ( Figure 3 , lanes a1, 2; lanes b1-3). Significantly, among the protein samples initially immunoprecipitated with the FLAG antibody, only those that had been transfected with gene-specific expression vectors showed positive signals for both cyclin B1 and CDK1 ( Figure 3 , a4 (for FLAG-TSPY); b5 (FLAG-SET), b6 (FLAG-TSPX)), whereas those transfected with the vector alone did not show any signals (Figure 3, a3; b4) . The results demonstrated that the endogenous cyclin B1 interacted with TSPY, TSPX and SET and was co-immunoprecipitated with these interactive proteins in the respective transfected 293 cell populations. The fact that CDK1 was co-immunoprecipitated with cyclin B1-TSPY/TSPX/SET suggested that it was also part of complexes consisting of these SET/NAP domain-containing proteins and cyclin B1. Hence, TSPY, TSPX and SET not only interacted with cyclin B1, but also with an activated cyclin B1-CDK1 complex.
TSPY colocalizes with cyclin B1 and CDK1 in interphase and mitotic cells
We had previously demonstrated a colocalization of TSPY and cyclin B1 in carcinoma in situ (CIS)/ intratubular germ cell neoplasia unclassified (ITGCNU) (Li et al., 2007a, b) and tumor cells of gonadoblastoma and seminoma specimens (Supplementary Figures S2 and S3 respectively) . To provide more details on possible subcellular locations of these proteins, transiently transfected cells were analysed with specific antibodies against TSPY and cyclin B1. The subcellular locations of cyclin B1 are cell-cycle stage dependent. It is S-labeled human cyclin B1 to GST-TSPY could be competitively displaced by increasing amount of His-tagged TSPX recombinant protein (His-TSPX). Input ¼ 10% of labeled protein used for each binding reaction; GST, GST alone; þ , present; À, absent of the respective protein.
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primarily located in the cytoplasm during most stages of the cell cycle, migrates to the nucleus in upon initiation of cell division and is degraded upon mitotic exit by the anaphase-promoting complex ubiquitination system. In transfected cells, TSPY was localized with cyclin B1 in the cytoplasm of cells presumably at interphase (Figure 4a ). When cyclin B1 was localized at the nucleus during prophase, similar nuclear location of TSPY could also be observed (Figure 4b ). At mitosis, both proteins were preferentially located at the microtubules of the mitotic spindles (Figure 4c ). Significantly, similar colocalization of TSPY and CDK1 could also be observed at prophase and metaphase cells (Figures 4d and e respectively). Selected mitotic cells at prometaphase, metaphase, anaphase and cytokinesis showed that TSPY was abundantly distributed in these cells (Figure 4f ). Again, preferential location of TSPY could be observed in metaphase cells (for example, Figure 4f , middle panel). To confirm its mitotic spindle location, these cells were analysed with both TSPY and a-tubulin immunofluorescence. Our results showed that TSPY was indeed located at the a-tubulin-containing microtubules of the mitotic spindles in metaphase and anaphase cells (Figures 4g and h ).
TSPY and TSPX exert opposite effects on the phosphorylation activities of a cyclin B1-CDK1 complex in vitro and in vivo The co-immunoprecipitation of the endogenous CDK1 and cyclin B1 with TSPY, SET and TSPX suggested that these SET/NAP domain-containing proteins could interact with an activated cyclin B1-CDK1 complex in the host cells. This postulation raised the possibility that these SET/NAP proteins could exert their effects on cyclin-dependent kinase activities by their interactions with cyclin B1 of the active enzyme complex. To validate our hypothesis, we had investigated the effects of each of three SET/NAP proteins in a reconstituted protein phosphorylation system consisting of activated cyclin B1-CDK1 enzyme complex, its substrate histone H1 (Figure 5e ) repressed the CDK1 kinase activities at dosage-dependent manners. Significantly, the enhancement and repression effects of TSPY and TSPX/SET were competitive in nature, such that the respective effects could be neutralized by those of opposite action (Figure 5d for TSPY and TSPX; Figure 5f for TSPY and SET respectively).
As structurally the significant differences between the TSPY and TSPX/SET are located at the acidic domains of both SET and TSPX, which is absent in TSPY (Lau et al., 2007) , we had addressed the probable roles of these acidic tails in modulating the cyclin B-CDK1 kinase activities. Recombinant proteins for TSPY, TSPX and SET truncated immediately beyond the respective SET/NAP domains were synthesized ( Figure 5g ) and used in the in vitro kinase activity assays. Truncation of the small carboxyl tail of TSPY did not affect its enhancement on the activity of an activated cyclin B1-CDK1 complex (Figure 5h ). Truncation of the respective acidic domains at the C termini of both TSPX and SET reversed their repression functions, resulting in various degrees of enhancement of cyclin B1-CDK1 kinase activities on the histone H1 substrate (Figures 5i and j, respectively) . As the prolinerich domain was present in the TSPXN truncated protein, our observations suggested that this N-terminal domain probably did not contribute to the TSPX repression of cyclin B1-CDK1 functions. Significantly, replacing the short carboxyl tail of TSPY with the long acidic tail of TSPX resulted in severe repression of cyclin B1-CDK1 kinase function (Figure 5k ), as observed with Colocalization of TSPY (red) with tubulin (green) at the mitotic spindles at metaphase (g) and anaphase (h). Merged, merged images of the respective fluorescence staining to the left. DAPI (4-6-diamidino-2-phenylindole; blue), DNA staining (see online version for colour figure).
the intact TSPX (Figure 5c ). These results clearly demonstrated that the domain responsible for TSPX repression on activated cyclin-dependent kinase function is located at its acidic carboxyl tail.
To determine the in vivo effects of these SET/NAP domain containing proteins on cyclin B1-CDK1 functions, we had analysed the cyclin B1-CDK1 kinase activities in transfected cells using the CycLex Figure 5 In vitro phosphorylation of histone H1 by an activated cyclin B1-CDK1 complex. (a) diagrammatic illustration of testisspecific protein Y-encoded (TSPY), SET, TSPX and (g) the respective variant recombinant proteins used in the cyclin B1-CDK1 kinase assays. TSPY (b) enhanced and TSPX (c) and SET (e) repressed the CDK1 kinase activities on its substrate in dosage-specific manners. The TSPY enhancement of CDK1 activities could be suppressed by addition of TSPX (d) or SET (f) in the reactions. Deletion of the small C terminus beyond the SET/NAP domain in TSPY showed minimal effects on its enhancement of the cyclin B1-CDK1 phosphorylation (h), whereas similar deletions of the acidic domains of TSPX (i) or SET (j) reversed the respective repression to moderate enhancement of the same kinase complex. Fusion of the TSPX acidic tail to the C terminus of TSPY resulted in significant repression of the cyclin B1-CDK1 kinase activities (k), similar to the same effects by intact TSPX protein (c). The relative fold changes were derived from densitometry scanning and calculated with reference to the average of cyclin B1-CDK1 activities in the control reactions without the respective recombinant protein(s) in each experiment.
Cdc2-Cyclin B Kinase Assay Kit. This kit utilized an anti-phospho-Cdc7-Threonine376 monoclonal antibody to detect the CDK1/cyclin B phosphorylation of its specific substrate, Cdc7. Hence, detection of a phosphorylated form of Cdc7 was proportional to the relative amount of activated cyclin B1-CDK1 kinase in the transfected and control cells (Masai et al., 2000) . Our results demonstrated that HEK293 cells transfected with the vector alone showed moderate cyclin B1-CDK1 kinase activities. Transfection of the same cells with expression vectors for TSPY type 1 and 2 individually elevated the in vivo cyclin B1-CDK1 kinase activities whereas expression of SET and TSPX repressed such activities in the same assay (Figure 6a) . Inclusion of roscovitine, a specific inhibitor for cyclin B1-CDK1 (Whittaker et al., 2007) , in parallel assays reduced the detectable cyclin B1-CDK1 kinase activities to uniformly minimal levels in all samples, supporting the specificity of the cyclin B1-CDK1 activities in this system. To confirm that these effects were consequences of the transfected gene-expression vectors, western blot was performed on total cell lysates of transfected and control cells with various specific antibodies. Using a monoclonal antibody against the FLAG epitope, the respective epitope-tagged SET/NAP proteins could be detected in all cells transfected with the corresponding expression vector (Figure 6b , lanes 2-5), except those transfected with vector alone (Figure 6b , lane 1). To confirm that the endogenous cyclin B1-CDK1 complexes were present in these cell lysates, parallel western blots were probed independently with specific antibodies against cyclin B1 and CDK1. The results confirmed the presence of endogenous cyclin B1-CDK1 complexes in the respective cell lysates (Figure 6c ), used in the cyclin B-dependent kinase assays. Our findings, taken together, demonstrated that TSPY exerted an enhancing function, whereas its X-homologue, TSPX and the related SET phosphoprotein exerted various repression functions on cyclin B1-CDK1 complex activities, leading to an expedition and retardation of G 2 /M phase transit respectively in the host cells.
Discussion
TSPY is a unique member of the SET/NAP protein family and does not harbor an acidic C terminus frequently present in other members (Lau et al., 2007) . Significantly, TSPY-like genes have been identified throughout the mammalian genomes (Vogel et al., 1998; Lau et al., 2007) . These TSPY-like genes are mostly functional, that is, capable of producing transcripts, although they might possess various spatiotemporal patterns of expression. In most cases, they are results of retrotransposition events of TSPY-derived transcripts as they are single exon genes whose open reading frames encode proteins similar to TSPY without the acidic domain. TSPX, on the other hand, was initially considered as a TSPY-like gene, termed TSPYlike 2. It has been independently isolated in various systems and has been designated as CDA1, DENTT and CASK-interacting nucleosome assembly protein (Chai et al., 2001; Ozbun et al., 2001; Wang et al., 2004a) . Recent studies on the gene organization and encoded proteins showed that its gene structure is closely related to that of TSPY, including conservation of intron-exon junctions and sequences, particularly at SET/NAP domain, but with exceptions at their amino and C termini that encode a proline-rich and acidic domain, respectively (Delbridge et al., 2004; Lau et al., 2007) . These studies suggest that TSPY-, TSPX-and TSPYlike genes could constitute a subfamily of SET/NAP domain-containing proteins (Lau et al., 2007) . Currently the exact functions of this gene family are uncertain. Mutation that truncates the SET/NAP domain in TSPY-L1 gene are associated with the sudden infant death with dysgenesis of the testis syndrome on chromosome 6 (Puffenberger et al., 2004) , suggesting that the SET/NAP domains are important for the respective functions of TSPY subfamily of proteins.
Results of the present study further substantiate Although the TSPY array is located at the critical region and is the putative gene for GBY locus on the human Y chromosome (Salo et al., 1995; Tsuchiya et al., 1995) , its exact oncogenic mechanism(s) in the disease process is still uncertain. The present studies have demonstrated that TSPY exerts such cell-cycle regulatory functions by directly interacting with type B cyclins and enhancing the cyclin B-CDK1 activities, resulting in an accelerated progression through G 2 /M of the cell cycle (Oram et al., 2006) . Significantly, cyclin-dependent kinase activity is essential for maintaining the integrity of the mitotic spindle checkpoint. The apparent preferential colocalization of TSPY protein with cyclin B1, CDK1 at the mitotic spindles of the metaphase cells suggests that TSPY could affect the cyclin B1-CDK1 functions on the spindles (Pines and Hunter, 1992; Richter, 2001; Smits and Medema, 2001; Porter and Donoghue, 2003; Wang et al., 2004b; Fukasawa, 2007) , thereby disrupting this mitotic checkpoint that could potentially result in chromosome nondisjunction and aneuploidy. Indeed, precursors of testicular germ cell tumors, that is, CIS/ITGCNU, could express TSPY at relatively high levels, whereas the resulting TGCTs are usually aneuploid (Looijenga and Oosterhuis, 2002; Oosterhuis and Looijenga, 2005; Rajpert-De Meyts, 2006) , thereby supporting the notation that overexpression of TSPY could increase genomic instability. Conversely, TSPX, the X-located homologue, and SET oncoprotein are also capable of interacting with cyclin B (Kellogg et al., 1995) , but exert an inhibitory function on the cyclin B1-CDK1 complex. As overexpression of TSPX (CDA1) or SET arrested cells at G 2 /M stage and retarded cell-cycle progression (Chai et al., 2001; Canela et al., 2003) , their inhibitory actions on cyclin B-CDK1 activities could contribute to such cell-cycle dysregulation. Using immunoprecipitated cyclin B-CDK1 complex from cultured cells, Canela et al. (2003) had also demonstrated similar inhibitory actions on cyclin B-CDK1 activities by SET protein in a dosage-dependent manner (Canela et al., 2003) . Our deletion mapping and domain swapping results further showed that the carboxyl acidic tail of TSPX (and SET), which is absent in TSPY, is important in cell-cycle modulation. Indeed, truncation of the acidic domain in TSPX abolished such inhibitory effects on cell-cycle progression and cyclin B-CDK1 activities, thereby confirming the significance of this domain (or lack of it) in the biological functions of TSPX and TSPY.
TSPY and TSPX have been postulated to evolve from the same ancestral gene on the proto-sex chromosomes (Graves, 1995; Lau et al., 2007) . TSPY is normally expressed in male early germ cells during embryogenesis, and spermatogonia, spermatocytes and, to certain extent, the round spermatids, in adult testis (Zhang et al., 1992; Schnieders et al., 1996; Honecker et al., 2004; Lau, 2005, 2006) , whereas TSPX is expressed ubiquitously in numerous cells/tissues (Ozbun et al., 2001 (Ozbun et al., , 2003 (Ozbun et al., , 2005 Delbridge et al., 2004; Wang et al., 2004a; Lau et al., 2007) . Such expression patterns suggest that TSPX could maintain a house-keeping function(s) in modulating cyclin B-CDK1 activities, and hence, cell-cycle progression, especially on G 2 /M transition, whereas TSPY has acquired various special functions pertaining to male stem germ cell proliferation and meiotic division. Significantly, male meiotic division involves two rounds of chromosome divisions without an intermediate interphase (Rajesh and Pittman, 2006; Bowles and Koopman, 2007) . TSPY interaction with cyclin B and enhancement of the cyclin B-dependent kinase activities could potentially be important for such consecutive chromosome divisions. When ectopically expressed in somatic cells incapable of male meiosis, the TSPY actions on cyclin B and CDK1 might accelerate cell proliferation (Oram et al., 2006) , affect G 2 /M checkpoints and increase in chromosome nondisjunction and genome instability (Lobrich and Jeggo, 2007; Schmit and Ahmad, 2007; Decordier et al., 2008) . Currently, it is uncertain how such cell-cycle dysfunction could lead to upregulation of selected oncogenes and pro-growth genes observed in cells overexpressing TSPY. Conceivably, other oncogenic events could exacerbate tumorigenesis associated with dysregulated TSPY expression. The TSPY array possesses the highest mutation rate among the key regions, that is, TSPY gene array, AZFc, Yq heterochromatin and IR3/IR3 region, of the human Y chromosome (Repping et al., 2006) . Significantly, nonallelic homologous recombination among its repeat units has been detected among normal and disease populations (Repping et al., 2006; Vijayakumar et al., 2006) . Hence, epigenetic dysregulation and genomic instability, instead of specific mutations of the coding sequences, of the TSPY array could constitute to the oncogenic and/or tumor predisposition properties of this tandemly repeated gene on the human Y chromosome.
Materials and methods
Plasmids and antibodies
Various cDNAs for TSPY, TSPX, SET, cyclin A, cyclin B1, B2 and B3 (variant 2) were inserted in pGEX4T3 vector for syntheses of GST fusion proteins in bacteria, in pET28b for in vitro protein syntheses, and in FLAG-epitope tagged p3XFLAG-CMV-7 vector (Sigma, St Louis, MO, USA) for expression in mammalian cells. Anti-TSPY monoclonal (M7) and polyclonal antibodies were previously described (Kido and Lau, 2005) . Other antibodies were purchased from commercial vendors.
Protein purification and GST pull-down assay GST recombinant proteins were synthesized in BL21(DE3) pLysS bacterial hosts and purified by affinity chromatography using glutathione-Sepharose beads, as previously described (Oh et al., 2005; Li et al., 2006) . GST pull-down assays were performed with respective GST fusion proteins and corresponding labeled proteins synthesized with the TnT T7 Quick Coupled Transcription/Translation System (Promega, Madison, WI, USA) in the presence of 35 S-methionine (Amersham Biosciences, Piscataway, NJ, USA). Specific polypeptides were conjugated to BrCN-activated Sepharose 4B (Amersham Biosciences) or MicroLink Peptide Coupling kit (Pierce Biotechnology, Rockford, IL), and used in pulldown assays with 35 S-methinione-labeled cyclin B1. The bound proteins were analysed in 10-15% SDS-PAGE gels and detected by autoradiography.
Cell synchronization and Co-immunoprecipitation Human HEK293 cells were transfected with p3 Â FLAG vector, p3 Â FLAG-TSPY, p3 Â FLAG-SET and p3 Â FLAG-TSPX plasmids using FuGENE 6 reagents (Roche, Indianapolis, IN, USA), and synchronized at G 2 /M phase, as before (Oram et al., 2006) . Co-immunoprecipitation was performed with a monoclonal anti-FLAG RedView antibody (Oh et al., 2005; Li et al., 2006) . The immunocomplexes were analysed by SDS-PAGE electrophoresis and western blot with rabbit anti-cyclin B, CDK1 or FLAG antibody.
Immunofluorescence microscopy
Immunofluorescence was performed on transfected HEK293 or COS7 cells, using various primary antibodies, detected by respective Alexa 488 or Alexa 568-þ conjugated secondary antibodies, counterstained with DAPI, and analysed as described (Oh et al., 2005; Li et al., 2006) .
Cyclin B-CDK1 activity in vitro and in vivo
In vitro cyclin-dependent kinase assays were performed with respective recombinant proteins of TSPY, TSPX, SET and TSPY-TSPX chimera and cyclin B1/CDK1 active complex (Calbiochem, San Diego, CA, USA). Various amounts (0.5, 1, 2, 4 mg) of purified recombinant proteins and two units of cyclin B1/CDK1 complex were used in kinase assay of 2 mg of histone H1 (Upstate Biotechnology, Lake Placid, NY, USA) in 20 ml buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 , 2 mM dithiothreitol, 1 mM ethylene glycol tetraacetic acid, 10 mM ATP and 2 mCi of [ 32 P]ATP (Amersham Biosciences)) at 30 1C for 30 min. Samples were resolved in 12% SDS-PAGE gels and analysed by autoradiography. Results were quantitated by densitometry scanning and NIH ImageJ Program and calculated as fold changes with respect to control reactions without recombinant proteins.
In vivo CDK1 kinase activity was analysed using the reaction kit, CycLex Cdc2-Cyclin B Kinase Assay Kit (MBL International, Woburn, MA, USA), according to the manufacturer's protocol. HEK293 cells were transfected with various TSPY/TSPX/SET expression vectors for 36 h and were then synchronized at G 2 /M by colcemid treatment for 12 h and analysed with CycLex Cdc2-Cyclin B Kinase Assay Kit. The absorbance was measured by using a spectrophotometric plate reader (SpectraMAX 250; Molecular Devices, Sunnyvale, CA, USA). All assays were performed in triplicates. Individual protein levels were determined by western blot of the same samples with respective FLAG, cyclin B1, CDK1 and tubulin antibodies.
